Scilex Holding Company (SCLX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Scilex Holding Company.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 6.60 $ — 3% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralScilex verkauft nicht-opioide Schmerzmittel; im eigenen Geschäft kommt KI nicht vor: keine KI-Umsatzquelle, kein belegter operativer KI-Einsatz. Der 10-K 2025 enthält nur den generischen Risikoabschnitt »Risks Related to Artificial Intelligence« ohne konkreten Bezug zum eigenen Geschäftsmodell (zählt laut Kriterienkatalog nicht als »bedroht«); der 10-Q Q1 2026 nennt lediglich ein unverbindliches Term Sheet über eine KI-Apotheken-Plattform eines Partners (Wellgistics/DelivMeds AI). Die KI-Anmutung der Aktie stammt allein aus dem Namen der Finanzbeteiligung Datavault AI (~48 Prozent, per Bitcoin bezahlt) — eine Beteiligung ist kein KI-Produktumsatz. Negativ-Befund per Volltext-Prüfung von 2×10-K und 4×10-Q auf »artificial intelligence«, »machine learning«, »generative«: in den Filings vor GJ 2025 null Treffer (alle »generative«-Funde sind »regenerative/degenerative«-Fehltreffer aus der Medizin).
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-05-20 · 10-Q 2025-11-14 · 10-Q 2025-08-13 · 10-Q 2025-05-14 · 10-K 2026-04-10 · 10-K 2025-03-31
Rated on July 8, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 7,324.2% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.92 | – | 15 | 10.70 | -43.40 | 3 | 2 |
| 2025: Q1 | -3.71 | – | 5 | -54.00 | -521.20 | 6 | 6 |
| 2025: Q2 | -12.24 | – | 10 | -39.50 | -869.70 | 7 | 7 |
| 2025: Q3 | -36.58 | – | 11 | -26.80 | -2,435.90 | 8 | 9 |
| 2025: Q4 | -4.71 | – | 5 | -67.80 | -690.80 | -18 | -18 |
| 2026: Q1 | -6.15 | – | 9 | 72.10 | -502.40 | -1 | -4 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Scilex Holding Company konzentriert sich auf Erwerb, Entwicklung und Vermarktung nicht-opioider Schmerzmanagementprodukte zur Behandlung akuter und chronischer Schmerzen. Zu den kommerziellen Produkten gehört ZTlido (Lidocain-topisches System) 1.
| Employees | 34 |
|---|---|
| Headquarters | Palo Alto, CA |
| Website | scilexholding.com |
| IPO Date | 5. Mar 2021 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Henry H. Ji Ph.D. | CEO, President & Executive Chairman | 1964 |
| Stephen Ma | Senior VP, CFO, COO, Corporate Secretary & Director | 1973 |
| Suketu D. Desai Ph.D. | Interim Chief Technical Officer & Senior VP | 1966 |
| Gigi DeGuzman | VP & Chief People Officer | – |
| Suresh K. Khemani | Senior VP, Chief Commercial Officer & GM of Scilex Pharma | 1960 |
| Dmitri V. Lissin M.D. | Senior VP of Clinical Development and Medical Affairs & Interim Chief Medical Officer | 1959 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.